Recipient of the Hubei Provincial "Hundred Talents" Program and Professor at Wuhan Institute of Technology. He earned his PhD in Pharmaceutical Sciences from Trinity College Dublin, Ireland, and previously served as a Research Scientist at Simcyp UK. His research focuses on in vitro simulation of pharmacokinetics and drug metabolism. He independently developed the Virtual Bioequivalence (VBE) platform, completed 7 FDA submissions with subsequent approvals, and has applied VBE technology to over 50 generic drug consistency evaluation projects, with extensive experience supporting clinical development of more than 20 innovative drug candidates.
Prof. Xu holds a PhD in Computer Science from the University of California, Irvine. Her research findings have been published in top academic conferences including the International Conference on Software Engineering (ICSE) and Foundations of Software Engineering (FSE). She received the Outstanding New Research Scholar Award at the 2006 Grace Hopper Celebration of Women in Computing.
PhD from the University of Connecticut, USA. He leads the architecture and development of the B²O software platform, with prior senior IT management experience at U.S. financial institutions. He oversees full-cycle platform architecture design, evaluation and big data development, as well as the foundational construction of AI and big data infrastructure, with solid expertise in software engineering and cross-functional project management.
Expert in quantitative clinical pharmacology with nearly 20 years of cross-sector experience spanning regulatory agencies (U.S. FDA) and industrial consulting (Certara). She is a pioneer in advancing Model-Informed Drug Development (MIDD) strategies, with a proven track record supporting regulatory submissions from pre-IND exploratory trials to full New Drug Application (NDA) approvals.